Latest From Alcon Inc.
The Swiss biotech believes the clinical success of OCS-01, a novel eye drop formulation of dexamethasone for diabetic macular edema, validates not only the drug but also Oculis's proprietary technology, allowing it to build up a pipeline of products for both retinal and front of the eye diseases.
OTC Decisions In February: 2 Switches, Label Changes For Excedrin, FeverAll, Naproxen From Biopharma
FDA approved two switches on one day in February, diclofenac gel and olopatadine ophthalmic drops, and stayed busy on OTCs through the month with label changes for Excedrin Migraine packaged with 2-count pouches and for Taro's FeverAll suppositories, and an NDA approval for Biopharma's naproxen.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Alcon Inc.
- Senior Management
David Endicott, CEO
Timothy C Stonesifer, SVP, CFO
Franck Leveiller, SVP, Head, Global R&D
Laurent Attias, Head, Global Corp. Dev. Strategy, BD&L, & M&A
Ed McGough, SVP, Global Mfctng. & Technical Operations
- Contact Info
Avenue Louis-Casaï 58
Cointrin-Geneva, TX CH-1216
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.